Original Article

Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

Shashikant Sharma1*, Vishali Gupta2, Aniruddha Maiti3, Sribhargava Natesh4, Sandeep Saxena5, Vivek Dave6, Vimal Parmar7, Raju Sampanji8, Hemanth Murthy9, Sandhya Dharwadkar10, Naresh Kumar Yadav11, Shrinivas Joshi12, Rahul Mayor13, Dhanashree Ratra14, Soumyava Basu15, Neha Goel16,17, Alok Chaturvedi1, Ronak Patel18 and Vinu Jose19

Abstract

Background: Razumab™ (world’s first biosimilar ranibizumab) is approved for several macular disorders including wet age-related macular degeneration (AMD). We evaluated the safety and efficacy of biosimilar ranibizumab in wet AMD.

Methods: This prospective, multicentre, rAnibizumab bioSimilar Safety Efficacy postmarkeTing (ASSET) study enrolled patients aged ≥50 years with wet AMD having best-corrected visual acuity (BCVA) between 20/40 and 20/320. The patients received intravitreal biosimilar ranibizumab 0.5 mg every 4 weeks for 24 weeks. Safety endpoints included the incidence of adverse events (AEs), serious AEs (SAEs), and immunoreactivity after 6 months. The efficacy endpoints were the proportion of patients who lose fewer than 15 letters, increase in BCVA, change in central retinal thickness (CRT), and change in Visual Function Questionnaire-25 (VFQ-25) score, from baseline to 24 weeks.

Results: Of the 126 enrolled patients, majority (95.24%) of the patients received all 6 doses of biosimilar ranibizumab (total 3 mg). Nineteen AEs were reported (n = 16; 12.7%); majority (78.9%) were mild. There were no serious AEs reported, except one AE of death which was unrelated to the study drug. None of the patients discontinued the study due to an AE. The most common ocular AE was increase in intraocular pressure (4 events) and non-ocular AE was pyrexia (5 events). A total of 7.9% (10/126) patients prior to dosing and 7.1% (9/126) patients post-treatment were positive for anti-ranibizumab antibodies. No AEs suggestive of immunogenicity were noted. At 24-weeks, 97.60% patients in the intent-to-treat (ITT) population (N = 125) and 97.41% patients in the per-protocol (PP) population (N = 116) lost < 15 letters from baseline visual acuity. In the ITT and PP populations, 31.20% and 32.76% patients, respectively, showed improved visual acuity by ≥15 letters. Significant improvements in BCVA (mean difference: 8.8, 9.2, p < 0.001 for ITT, PP) and VFQ-25 (8.5, 9.2, p < 0.001 for ITT, PP) were seen; CRT reduced significantly (125 µm, 119.3 µm, p < 0.001 for ITT, PP).

© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Age-related macular degeneration (AMD) is a progressive neurodegenerative disease and a leading cause of visual loss in elderly patients [1]. Wet (exudative) AMD begins with neovascularization from choroid due to defects in the Bruch’s membrane. Neovascular vessels proliferate underneath the retinal pigment epithelium, and leakage from these vessels leads to retinal elevation resulting in blurring of vision [2, 3]. In India, the prevalence of AMD is estimated between 1.4% and 3.1% with advanced age (> 65 years) being the most common factor affecting the prevalence of AMD [4]. The global prevalence of AMD is estimated at ~ 8.7% [5]. Though wet AMD accounts only for 10% to 15% of all the AMD cases [6], 80% of these patients develop severe vision loss [7].

Vascular endothelial growth factor (VEGF)-A plays a vital role for angiogenesis and vascular permeability, and it is overexpressed in wet AMD [8, 9]. Anti-VEGF agents, pegaptanib, ranibizumab and aflibercept are approved [3, 10] while bevacizumab is used off-label for the treatment of wet AMD [11, 12]. Ranibizumab is a humanized monoclonal antibody approved in the United States since June 2006 [13] and in Europe since January 2007 [14]. Ranibizumab binds with a high affinity to VEGF-A isoforms and prevents the interaction of VEGF-A with its receptors VEGFR-1 and VEGFR-2 on the surface of endothelial cells [2].

Intas Pharmaceuticals Limited, India, has developed Razumab™, the world’s first biosimilar ranibizumab, which has been approved (permission no. MF-35/2015 BULK-36/2015, Dated 26th February 2015) by the highest Indian regulatory authority ‘Drugs Controller General of India (DCGI)’ for the treatment of neovascular (wet) AMD, diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO) and for visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia [15]. The efficacy and safety of biosimilar ranibizumab has been established with prospective as well as retrospective studies for the treatment of several macular disorders including wet AMD, DME, RVO and myopic CNV [16–22]. In this article, we present the results on the safety, immunogenicity and efficacy of biosimilar ranibizumab in Indian patients with wet AMD from a prospective, post-marketing study.

Methods
Study design
The ASSET (rAnibizumab bioSimilar Safety Efficacy postmarketing) was a phase 4, prospective, interventional, single-arm, non-comparative, multicentre, post-marketing study to evaluate the safety and efficacy of the world’s first biosimilar ranibizumab, Razumab™, in patients with wet AMD (Clinical Trial Registry Number: CTRI/2016/03/006739). The first patient was enrolled on 01 June 2016 and the last patient completed the study on 06 June 2018. The study was conducted at 16 sites across India. The study protocol was approved by an institutional ethics committee of the respective study center. The study was conducted in accordance with the Declaration of Helsinki, good clinical practices and relevant regulatory guidelines. All patients provided written informed consent before enrolment into the study.

Patients
We enrolled patients of either gender, aged ≥ 50 years, having active primary or recurrent sub-foveal lesion with CNV secondary to AMD, involving the foveal center, and having a best corrected visual acuity (BCVA) of 20/40 to 20/320 using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart (Snellen equivalent) in the study eye. Only one eye was evaluated, and if both eyes were eligible for inclusion, the eye with the better visual acuity was selected unless the investigator chose the other eye for treatment on medical grounds.

Patients were excluded if they had received prior treatment with any intravitreal drug, ranibizumab, verteporfin or photodynamic therapy within the past three months; or had received prior treatment with systemic or intra-vitreal bevacizumab within the last six months; or underwent extrafoveal laser photoacoagulation within one month in the study eye; had subfoveal fibrosis or atrophy in the study eye, had CNV in either of the two-eyes due to causes other than AMD; had intraocular condition that could require any intervention during the six months study period; had vitreous haemorrhage or rhegmatogenous retinal detachment or macular hole (stage 3 or 4); had active intraocular inflammation or ongoing infection; had a recent history of stroke, or a patient with known hypersensitivity to ranibizumab.

Conclusion: Razumab™ (world’s first biosimilar ranibizumab) was well-tolerated without new safety concerns and significantly improved visual acuity in wet AMD patients.

Trial registration CTRI/2016/03/006739. Registered 18 March 2016—Prospectively registered, http://ctri.nic.in/ClinicalTrials/pmaindet2.php?trialId=13141&EncId=2016/03/006739

Keywords: Razumab, Biosimilar ranibizumab, Neovascular, Wet age-related macular degeneration, AMD, Safety
Treatment and follow-up
Patients were screened within 4 weeks before study enrolment. Eligible patients received intravitreal injections of biosimilar ranibizumab at a dose of 0.5 mg every 4 weeks for 24 weeks for a total of 6 doses. A total of 16 study visits were planned for each enrolled patient including the screening visit and the end of study visit (Fig. 1). Patients were followed-up for evaluations the next day after study drug administration.

Safety assessments
The safety endpoints included the incidence of adverse events (AEs) and serious AEs (SAEs) including any hypersensitivity reactions, any significant laboratory abnormalities, and the proportion of patients developing anti-ranibizumab antibody after 6 months of treatment.

Fundus fluorescein angiography (FFA) was performed for all patients on the day of screening to assess the lesion severity. The spectral domain-optical coherence tomography (SD-OCT) examinations were performed on the day of screening, baseline visit and at 3- and 6-months post-treatment visits. Slit-lamp examination, indirect ophthalmoscopy, and intraocular pressure measurements were done at screening, each dose administration visits and at the end of the study. Ophthalmic examination was done for safety assessment on the subsequent day of dosing using the safety questionnaire (Additional file 1: Appendix S1).

Other safety assessments included physical examination, vital signs assessment, chest X-ray, electrocardiograph, and routine laboratory evaluations. Adverse events were monitored during the study and coded using Medical Dictionary for Regulatory Activities (MedDRA) version 20.1.

Immunogenicity assessments
Immunogenicity was evaluated by assessing the presence of serum anti-ranibizumab antibodies in all patients. A total of 9 samples (baseline, Weeks 2, 4, 6, 8, 12, 16, 20 and 24), each of 6 mL, were collected from each patient to detect anti-ranibizumab antibodies in the serum. Blood samples were collected through the needle from a venipuncture site with the arm in downward position, and collected in vacutainers placed upright in a rack kept in ice cold water bath until centrifugation. The serum samples were centrifuged at 3000 ± 100 rpm for 10 min at room temperature (18–25 °C) to separate the serum. The serum samples were transferred using pasture pipette (dropper) to polypropylene cryovial in two aliquots (around 500 μL in first aliquot and remaining volume in second aliquot) and stored at a temperature of −22 °C ± 5 °C or below for interim storage until shipment for analysis. Samples were at controlled temperature (−22 °C ± 5 °C or below)/packed with dry ice for transport along with data logger. After receiving the samples at the Bioanalytical Laboratory of Lambda Therapeutic Research Limited, Ahmedabad, India, the samples were stored at −65 ± 10 °C until completion of analysis. The serum samples were analysed using a standard, globally acceptable and validated bridging enzyme-linked immunosorbent assay (ELISA) method for anti-ranibizumab antibodies at Lambda Therapeutic Research Limited.

Efficacy assessments
The efficacy assessments were done at baseline, Week 12 and end of the study (Week 24) using BCVA, central retinal thickness (CRT), and Visual Function Questionnaire (VFQ)-25 [23] parameters. The BCVA was assessed using the ETDRS visual acuity chart. The proportion of patients who lost fewer than 15 letters (approximately 3 lines) from baseline visual acuity at the end of the study, and mean increase in the BCVA in the study eye from baseline to the end of the study, were calculated. The central retinal thickness was measured by SD-OCT in the study eye and changes in the thickness of retina from baseline to the end of the study were calculated. The changes in

Fig. 1 Study assessment schedule
VFQ-25 score from baseline to the end of the study were also measured.

Sample size and statistical methods
Based on the requirement of the Indian apex drug regulator the ‘DCGI’ to generate the efficacy and safety data on Razumab in at least 100 patients, a total 126 patients were planned to be recruited into the study considering a drop out/withdrawal rate of ~20%. The safety variables were assessed using descriptive statistics such as number of observations, mean, standard deviation, median, and range for continuous variables, and percentages and frequency for categorical variables. The safety analysis was done on the safety population which was defined as patients who received at least one dose of biosimilar ranibizumab. The percentage of patients developing anti-ranibizumab antibodies during the 6 months of treatment along with the 95% CI was calculated in immunogenicity population, defined as the patients who received at least one dose of biosimilar ranibizumab in the study and had at least one pre-dose and one post-dose immunogenicity sample analysed.

The efficacy variables including change in BCVA, CRT and VFQ-25 were assessed using descriptive statistics and the p-value was calculated using paired t-test to compare changes from the baseline to 24 weeks. The proportion of patients who lost fewer than 15 letters was presented. The efficacy analysis was done on an intent-to-treat (ITT) and per protocol (PP) populations. The ITT population was defined as all patients who received at least one dose of study treatment and had at least one efficacy assessment data. The PP population was defined as patients who completed the study without major protocol deviations impacting efficacy evaluations. The last observation carried forward (LOCF) approach was used to compute the missing data. Statistical analyses were done using SAS® Version 9.4 (SAS Institute Inc., USA).

Results
Patient disposition
A total of 149 patients were screened from 16 centres in India. Of which, 126 were enrolled and 23 were excluded as they did not meet the selection criteria (n = 11) or were not ready to provide consent for study participation (n = 12). All the 126 enrolled patients received biosimilar ranibizumab and were included in the safety and immunogenicity populations. The ITT population included 125 patients since one patient did not have any post-dose efficacy assessment due to deviation from the protocol procedure. Of the 126 patients, 116 (92.06%) completed the study and were included in the PP population; 10 (7.94%) patients did not complete the study since they did not return for follow-up (n = 1), died (n = 1), missed the visit (n = 1), investigator’s decision (n = 1) or withdrew consent (n = 6) (Fig. 2).

Demographics and baseline characteristics
Of 126 patients, majority (72.22%, n = 91) were males (Table 1). All patients were Asians (Indians). Hypertension (35.71%) and diabetes (23.80%) were the most common comorbidities. For ITT and PP populations, the baseline mean ± SD BCVA were 44.0 ± 16.27 and 44.4 ± 16.38 letters, CRT were 384.8 ± 146.44 and 379.7 ± 141.57 µm, intraocular pressure (IOP) for left eye were 14.4 ± 3.31 and 14.6 ± 3.33 mm Hg, IOP for right eye were 14.2 ± 3.12 and 14.3 ± 3.13 mm Hg, and VFQ-25 score were 60.9 ± 14.36 and 60.4 ± 14.14, respectively.

Biosimilar ranibizumab exposure
All 126 enrolled patients received at least one dose of biosimilar ranibizumab, of which 120 (95.24%) patients received all 6 doses of biosimilar ranibizumab (total 3 mg), 4 (3.17%) patients received 4 doses (total 2 mg) and 1 patient each received five doses (total 2.5 mg) and one dose (total 0.5 mg).

Safety
Of 126 patients, 16 (12.7%) patients reported a total 19 AEs during the study (Table 2). A patient with history of hypertension and asthma who had myocardial infarction (MI) 4 months before screening died following the 4th dose of biosimilar ranibizumab due to another MI event which was unrelated to the study drug. Except for this patient, none discontinued the study due to an AE. There were no other SAEs reported in the study.

Out of 19 AEs, only two AEs, iridocyclitis and increase in intraocular pressure, were considered related to the study drug. The mean ± SD IOP (mm Hg) decreased from baseline 14.5 ± 3.38 to 13.9 ± 2.74 for left eye, and from 14.2 ± 3.19 to 13.9 ± 2.97 for right eye at Week 24. Majority of the AEs were mild (n = 15), 3 AEs (corneal edema, iridocyclitis, increase in intraocular pressure) were moderate, and one AE (death) was severe. Except death, all other AEs resolved during the study. Out of 19 AEs, 10 AEs were ocular and were reported by 9 (7.14%) patients. The most common ocular AE was increase in intraocular pressure (4 AEs in 3 patients), followed by eye pruritus (2 AEs in 2 patients). The most common non-ocular event was pyrexia (5 AEs), reported in 5 (3.97%) patients. No event of hypersensitivity reaction to biosimilar ranibizumab was reported in the study.
Immunogenicity
A total of 10 (7.94%; 95% CI 3.22%, 12.66%) patients were positive for anti-ranibizumab antibodies prior to dosing, and 9 (7.14%; 2.65%, 11.64%), 5 (3.97%; 0.56%, 7.38%), 6 (4.76%; 1.04; 8.48%), 5 (3.97%; 0.56%, 7.38%), 8 (6.35%; 2.09%, 10.61%), 9 (7.14%; 2.65%, 11.64%), 9 (7.14%; 2.65%, 11.64%), and 8 (6.35%; 2.09%, 10.61%) patients at Weeks 2, 4, 6, 8, 12, 16, 20 and 24, respectively, were positive for anti-ranibizumab antibodies post treatment with biosimilar ranibizumab.

Efficacy
At the end of 24 weeks, visual acuity of treated eye improved in both ITT and PP populations as assessed by efficacy parameters such as the 15-letter loss for visual acuity, BCVA, CRT and VFQ-25 score.

The proportion of patients who lost fewer than 15 letters from baseline visual acuity was 98.40% (95% CI 96.20%, 100.60%) patients at Week 12 and 97.60% (95% CI 94.92%, 100.28%) patients at Week 24 in the ITT population, and 98.28% (95% CI 95.91%, 100.64%) patients at
**Table 1** Baseline patients characteristics

| Parameter (units) | Safety population (N=126) | ITT population (N=125) | PP population (N=116) |
|------------------|---------------------------|------------------------|-----------------------|
| Age (years), mean±SD | 68.75±8.64 | 68.65±8.61 | 68.69±8.61 |
| Height (cm), mean±SD | 159.91±9.72 | 160.11±9.50 | 159.97±9.34 |
| Weight (kg), mean±SD | 63.52±9.90 | 63.60±9.90 | 63.45±9.54 |
| BMI (kg/m²), mean±SD | 24.94±4.16 | 24.91±4.15 | 24.90±4.11 |
| Gender, n (%) | | | |
| Female | 35 (27.78) | 35 (28) | 32 (27.59) |
| Male | 91 (72.22) | 90 (72) | 84 (72.41) |
| Study eye, n (%) | | | |
| Left | 51 (40.48) | 50 (40) | 46 (39.66) |
| Right | 75 (59.52) | 75 (60) | 70 (60.34) |

BMI: body mass index, ITT: intent-to-treat, PP: per-protocol, SD: standard deviation

**Table 2** Adverse events (safety population)

| System organ class | Preferred term Biosimilar ranibizumab (N=126) |
|-------------------|-----------------------------------------------|
| Total events | 16 (12.70%) 19 |
| Eye disorders | 6 (4.76%) 6 |
| Corneal edema | 1 (0.79%) 1 |
| Dry eye | 1 (0.79%) 1 |
| Eye pruritus | 2 (1.59%) 2 |
| Iridocyclitis | 1 (0.79%) 1 |
| Ocular hyperaemia | 1 (0.79%) 1 |
| General disorders and administration site conditions | 6 (4.76%) 6 |
| Death | 1 (0.79%) 1 |
| Pyrexia | 5 (3.97%) 5 |
| Infections and infestations | 1 (0.79%) 1 |
| Nasopharyngitis | 1 (0.79%) 1 |
| Investigations | 4 (3.17%) 5 |
| Increased blood pressure | 1 (0.79%) 1 |
| Increase in intraocular pressure | 3 (2.38%) 4 |
| Nervous system disorders | 1 (0.79%) 1 |
| Headache | 1 (0.79%) 1 |

N: Number of patients, e: Number of events

Adverse events were categorized using MedDRA Version 20.1

Week 12 and 97.41% (95% CI 94.53%, 100.30%) patients at Week 24 in the PP population. The mean (SD) BCVA improved significantly from 44 (16.27) to 50.3 (17.37) letters at Week 12 (mean [SD] difference 6.3 [11.11] letters, p<0.0001) and 53.7 (17.83) letters at Week 24 (mean [SD] difference 9.2 [13.85] letters, p<0.0001) in the PP population (Fig. 3). The proportion of patients who showed improvement in the visual acuity by ≥15 letters from baseline to Weeks 12 and 24 were 23.20% and 31.20% for the ITT, and 24.14% and 32.76% for the PP populations, respectively.

The mean (SD) CRT significantly decreased from 384.8 (146.44) µm to 273.1 (101.34) µm at Week 12 (mean [SD] difference 110.6 [130.65] µm, p<0.0001) and 258.5 (74.77) µm at Week 24 (mean [SD] difference 125 [130.37] µm, p<0.0001) in the ITT population and from 379.7 (141.57) µm to 275.2 (102.59) µm at Week 12 (mean [SD] difference 104.1 [126.73] µm, p<0.0001) and 259.7 (74.00) µm (mean [SD] difference 119.3 [127.51] µm, p<0.0001) in the PP population (Fig. 4). The VFQ-25 scores also significantly improved from baseline to the end of the study (Table 3).

**Discussion**

The ASSET was a phase 4, single arm post-marketing, prospective study conducted to evaluate the safety and efficacy of the world’s first biosimilar ranibizumab, Razumab™, in patients with wet AMD. The biosimilar...
ranibizumab was well-tolerated in patients with wet AMD and showed a similar safety profile as that of the innovator ranibizumab reported in the literature [24]. The biosimilar ranibizumab was found efficacious in improving the overall wet AMD disease condition. The efficacy and safety of biosimilar ranibizumab has also been demonstrated in the previous real-world retrospective RE-ENACT and RE-ENACT 2 studies in patients with several macular disorders including wet AMD [18, 21].

In this study, we enrolled 126 patients of either gender with age \( \geq 50 \) years who had BCVA of 20/40 to 20/320 using ETDRS chart and who had active sub-foveal CNV in the study eye. Active CNV and age \( \geq 50 \) years are the major risk factors of wet-AMD patients leading to severe vision loss or blindness in the patients [25]. The study population was selected based on the innovator's ANCHOR, MARINA, HARBOR, PIER, and SUSTAIN studies in wet-AMD patient population [26–30]. The ANCHOR and MARINA studies have demonstrated that monthly ranibizumab regimen provides better benefits compared to other regimens with less frequent dosing as seen in HARBOR, PIER, SUSTAIN and IVAN studies [26–31]. Similarly, in our cohort, patients were administered 0.5 mg monthly regimen of intravitreal biosimilar ranibizumab.

In our study, patients were dosed for 6 months to assess the safety and efficacy of biosimilar ranibizumab, which was chosen considering improvement in visual acuity of wet AMD patients after receiving monthly ranibizumab in ANCHOR, MARINA, EXITE, SUSTAIN, and HARBOR studies [26–28, 30, 32]. These studies showed significant improvement in visual acuity by three months and patients could sustain the benefit till the end of the treatment period of 12 or 24 months. Therefore, we chose to assess efficacy of biosimilar ranibizumab till 6 months (total 6 doses). This was also supported by ProNTO and LUMIERE studies where patients received an average of 5 or 6 doses [33, 34]. We assessed the safety of biosimilar ranibizumab using standard eye examinations including fundus fluorescein angiography, slit-lamp examination, indirect ophthalmoscopy, and laboratory assessments [35, 36]. The efficacy of biosimilar ranibizumab was assessed using sensitive endpoints such as change in BCVA using ETDRS chart, change in CRT measured by SD-OCT, and changes in VFQ-25 which assessed vision-related activities during day to day life [37].

Of the 19 AEs reported in 16/126 (12.7%) patients, 10 were ocular AEs reported in 9 (7.14%) patients; increase in intraocular pressure was the most common AE. Of 4 AEs of increase in intraocular pressure, only one was considered related to the study drug. Increase in intraocular pressure have been noted both pre- and post-intravitreal injections [38]. The mean changes in IOP at the end of study were minimal (<1 mm Hg) and not significant in this study, similar to that reported in previous studies of biosimilar ranibizumab [17–19].

Iridocyclitis, corneal edema, ocular hyperaemia, and dry eye were observed in <1% of patients after biosimilar ranibizumab treatment. Similar incidence rates for these AEs were observed in the innovator ranibizumab postmarketing surveillance studies [7, 39]. The common (10%) ocular AEs reported for ranibizumab are conjunctival haemorrhage, eye pain, vitreous detachment or floaters, increase in intraocular pressure, intraocular inflammation, visual disturbance, eye

### Table 3  Visual function questionnaire-25 score

| VFQ-25 Score | ITT population (N = 125) | PP population (N = 116) |
|-------------|--------------------------|-------------------------|
| Baseline, mean ± SD | 60.9 ± 14.36 | 60.4 ± 14.14 |
| Week 12, mean ± SD | 66.7 ± 12.65 | 66.5 ± 12.50 |
| Mean ± SD change from baseline to Week 12 | 5.8 ± 10.78 [p < 0.001] | 6.1 ± 10.96 [p < 0.001] |
| Week 24, mean ± SD | 69.5 ± 12.46 | 69.5 ± 12.35 |
| Mean ± SD change from baseline to Week 24 | 8.5 ± 13.04 [p < 0.001] | 9.2 ± 13.33 [p < 0.001] |

*ITT intent-to-treat population, PP per-protocol population*
irritation, increased lacrimation, blepharitis, dry eye, ocular hyperaemia and eye pruritus [38].

In the current study, hypertension and nasopharyngitis were reported in one patient each. Incidence rates of hypertension, nasopharyngitis and headache ranged from 3 to 9%, while incidence rates of thromboembolic events ranged from 0.8 to 5.6% with innovator ranibizumab as reported in literature [26, 27, 30, 32, 40, 41]. Non-ocular AEs associated with systemic VEGF inhibition, such as arterial thromboembolic events, hypertension, proteinuria, and non-ocular haemorrhage are of particular interest [9, 12].

Of 126 patients, only one patient discontinued the study due to an AE, i.e. death due to MI. This AE was considered unrelated to the study drug. Important ocular SAEs such as endophthalmitis and vitreous haemorrhage, and non-ocular SAEs such as thromboembolic events, which were reported in some large clinical studies of innovator ranibizumab, were not reported in our study [26, 27, 30, 42, 43]. However, it is noteworthy that many interventional and observational postmarketing studies have also not reported any case of endophthalmitis [30, 32, 39]. In our study, anti-ranibizumab antibodies were seen in 7.94% patients before treatment and in 7.14% patients after biosimilar ranibizumab treatment, which is comparable to the pre-treatment immunoreactivity incidence of 0–5% and 1–9% after 6 to 24 months of innovator ranibizumab treatment [38]. In a study by Nicolas et al. the incidence of immunogenicity was 17.1% with innovator ranibizumab [44]. Moreover, there was no increased incidence of immunogenicity with the increase in the number of biosimilar ranibizumab injections administered in our study.

Patients with wet AMD lose visual acuity by 2 to 3 lines per year if the patient remains untreated [27, 45]. Biosimilar ranibizumab treatment showed benefit in visual acuity during the 24 weeks of treatment. At the end of the study (Week 24) for ITT and PP populations, 97.60% and 97.41% patients lost fewer than 15 letters, respectively, and visual acuity improved by 15 letters for 31.20% and 32.76% patients, respectively, from baseline to the end of the study. In ANCHOR and MARINA studies, 96.4% and 94.6% patients lost fewer than 15 letters respectively and visual acuity increased by 15 letters for 40.3% and 33.8% patients respectively after receiving a total of 12 doses of ranibizumab [26, 27]. The improvement in BCVA after 6 months of biosimilar ranibizumab treatment was 9.2 letters which was in line with 10.6 letters reported in the ANCHOR and 6.5 letters reported in the MARINA studies [26, 27]. The improvement in CRT (119.3 µm) observed in this study was also comparable with other studies of ranibizumab in patients with wet AMD [30].

The study limitations included the unavailability of details pertaining to the patterns, size and type of CNV (classic/occult/mixed). Also, the details of the patients who had received previous treatments before the timelines as mentioned in the exclusion criteria, were not captured, and hence, the data on ‘treatment naïve’ versus ‘previously treated patients’ could not be provided.

**Conclusions**

Overall, this prospective, postmarketing ASSET study of the world’s first biosimilar ranibizumab, Razumab™, in patients with wet AMD over 6 months showed similar safety and efficacy profiles to the evidence reported with innovator ranibizumab. Biosimilar ranibizumab was well-tolerated without any new safety concerns. Biosimilar ranibizumab also showed similar improvement in patients with wet AMD for 15 letter loss assessed by visual acuity, BCVA and retinal thickness, as reported with innovator ranibizumab. Long-term studies with a larger patient population may elicit better results.

**Abbreviations**

AE: Adverse event; AMD: Age-related macular degeneration; ASSET: Ranibizumab Biosimilar Safety Efficacy postmarketing; BCVA: Best corrected visual acuity; CNV: Choroidal neovascularization; CRT: Central retinal thickness; DCGL: Drugs Controller General of India; DME: Diabetic macular edema; ELISA: Enzyme-linked immunosorbent assay; ETDRS: Early Treatment Diabetic Retinopathy Study; FFA: Fundus fluorescein angiography; IOP: Intraocular pressure; ITT: Intent-to-treat; LOCF: Last observation carried forward; MedDRA: Medical Dictionary for Regulatory Activities; MI: Myocardial infarction; PP: Per protocol; RVO: Retinal vein occlusion; SAE: Serious adverse event; SD: Standard deviation; SD-OCT: Spectral domain-optical coherence tomography; VEGF: Vascular endothelial growth factor; VFQ: Visual Function Questionnaire.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s40942-021-00293-w.

**Acknowledgments**

We thank the study patients for their participation in this study. We thank Dr. Tanishq Sharma (Shree Krishna Hospital, Karamsad, Gujarat, India) for providing significant independent medical review of this manuscript. We also thank Mrs. Meghana Dahiya (Intas) and Mr. Parag Pipalava (Intas) for providing writing support, and Lambda Therapeutic Research Ltd, India, for conducting the study.

**Authors’ contributions**

SS, AC, and VJ participated in study conceptualization and design, data collection, data analysis and interpretation, and writing and review of the manuscript. RP participated in the study design, statistical analysis and review of the manuscript. All the authors participated in study design, data contribution, and review of the manuscript. All authors substantially contributed in interpretation of data, critical revision of manuscript, and consented to the final version of the manuscript. All authors had full access to all data of this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All authors meet ICME criteria and all those who fulfilled those criteria are listed as authors. All authors read and approved the final manuscript.
Funding
The study was funded by Intas Pharmaceuticals Limited, Ahmedabad, India.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study protocol was approved by an institutional ethics committee of the respective study center. All patients provided written informed consent before enrolment into the study. The study was conducted in accordance with the Declaration of Helsinki, good clinical practices and relevant regulatory guidelines.

Consent for publication
Not applicable.

Competing interests
Drs. Shashikant Sharma and Alok Chaturvedi are employees of Intas Pharmaceuticals Ltd, Ahmedabad, India and Dr. Vinu Jose is an employee of Intas Pharmaceuticals Ltd. (Biopharma), Ahmedabad, India. Mr. Ronak Patel is an employee of Lambda Therapeutic Research Limited, Ahmedabad, India.

Author details
1 Medical Affairs, Intas Pharmaceuticals Ltd, Ahmedabad, Gujarat, India.
2 Advanced Eye Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
3 Susrut Eye Foundation & Research Centre, Eye7 Chaudhary Eye Centre, New Delhi, India.
4 Department of Biostatistics Multi Speciality Hospital, Bangalore, Karnataka, India.
5 PBMA’s H. V. Desai Eye Hospital, Pune, Maharashtra, India.
6 Gurushree Hi-Tech Multi Speciality Hospital, Bangalore, Karnataka, India.
7 Retina Institute of Karnataka, Bangalore, Karnataka, India.
8 K.R. Hospital, Mysore Medical College & Research Institute, Mysore, India.
9 Narayana Nethralaya, Bangalore, Karnataka, India.
10 M M Joshi Eye Institute, Hubli, Karnataka, India.
11 Dr. Shroff’s Charity Eye Hospital, New Delhi, India.
12 Mankara Nethralaya, Chennai, Tamil Nadu, India.
13 L V Prasad Eye Institute, Hyderabad, Telangana, India.
14 Sankara Nethralaya, Chennai, Tamil Nadu, India.
15 Central Drugs Standard Control Organization, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India.
16 Grisanti S, Ziemssen F. Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol. 2007;55(6):417–20.
17 Kumar A, Tripathy K, Chawla R. Intracocular use of bevacizumab in India: an issue resolved? Natl Med J India. 2013;30(6):345–7.
18 Sameena W, Ayachit A, Joshi S, Guriuprasad AS. Safety and efficacy of ranibizumab—the new biosimilars in india: our experience. Kerala J Ophthalmol. 2016;28(28):180.
19 Clinical Development & Medical Affairs, Intas Pharmaceuticals Ltd. (Biopharma), Ahmedabad, Gujarat, India. https://cdsco.gov.in/opencms/deeplynested/container/jsp/record/download_file_division.jsp?num_id=NTU2Ng==. Accessed 25 Feb 2021.
20 Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. A multicenter, retrospective study (RE-ENACT 2) on the use of Razumab® (world’s first biosimilar ranibizumab) in retinal vein occlusion. Ophthalmol Ther. 2020;9(1):103–14.
21 Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real-Life clinical effectiveness of Razumab® (the world’s first biosimilar ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT study. Ophthalmologica. 2019;244(1):24–31.
22 Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real life clinical effectiveness of Razumab® (world’s first biosimilar ranibizumab) in wet age-related macular degeneration. Ophthalmol Ther. 2019;22(4):232–7.
23 National Eye Institute. Visual Functioning Questionnaire - 25 (VFQ-25). https://nei.nih.gov/sites/default/files/nei-pdfs/Vfq_sa.pdf. Accessed 4 Sept 2020.
24 Lucentis (ranibizumab) Summary of Product Characteristics. Novartis europharm limited. Last Updated: 10 August 2018. https://www.medicinae.org.uk/emc/product/307/summary. Accessed 4 Sept 2020.
25 Yuan J. Role of inflammatory factors in the effects of aflibercept or ranibizumab treatment for alleviating wet age-associated macular degeneration. Exp Ther Med. 2019;17(5):4249–58.
26 Brown DM, Kaiso PK, Michels M, Soubrane G, Heier JS, Kim RV, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–44.
27 Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiso PK, Chun CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31.
28. Busbee BG, Ho AC, Brown DM, Heier JS, Suher UJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–56.

29. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150(3):315-24.e1.

30. Holz FG, Amoako W, Donate J, Guymere RH, Kellner U, Schlingemann RO, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118(4):663–71.

31. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399–411.

32. Schmidt-Erfurth U, Eldem B, Guymere R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118(5):831–9.

33. Cohen SY, Mirmoun G, Oubraham H, Zourdani A, Malbrel C, Quéré S, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina. 2013;33(3):747–81.

34. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Nichols TS, Feuer WJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566–83.

35. Sadda SR, Chakravarthy U, Birch DG, Stasherg H, Henry EC, Brittain C. Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration. Retina (Philadelphia, Pa). 2016;36(10):1806–22.

36. The Foundation of the American Society of Retina Specialists. Age-related macular degeneration. https://www.asrs.org/content/documents/fact_sheet_16_amd_new.pdf. Accessed 4 Sept 2020.

37. Csaky K, Ferris F 3rd, Chew EY, Nair P, Cheetham JK, Duncan JL. Report from the NEI/FDA endpoints workshop on age-related macular degeneration and inherited retinal diseases. Invest Ophthalmol Vis Sci. 2017;58(9):3456–63.

38. Lucentis (ranibizumab) Prescribing Information. Genentech Inc., USA. Last Updated: March 2018. https://www.gene.com/download/pdf/lucentis_prescribing.pdf. Accessed 4 Sept 2020.

39. Ohno-Matsui K, Suzuki M, Teshima R, Okami N. Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan. Eye (Lond). 2018;32(12):1871–8.

40. Silva R, Axer-Siegel R, Eldem B, Guymere R, Kirchhof B, Papp A, et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):130–9.

41. Penedones A, Mendes D, Alves C, Batel MF. Safety monitoring of ophthalmic biologics: a systematic review of pre- and postmarketing safety data. J Ocul Pharmacol Ther. 2014;30(9):729–51.

42. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–908.

43. Antoszyk AN, Tuomi L, Chung CY, Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145(5):862–74.

44. Leveziel N, Pelat T, Watier H, Thullier P, Souied EH. Detection of antiranibizumab antibodies among patients with exudative age-related macular degeneration. Ophthalmologica. 2014;232(1):53–6.

45. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239–48.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.